Company Insights

ORMP customer relationships

Explore interactive graphBrowse insights index
ORMP customer relationship map

Oramed (ORMP) customer map: licensing, strategic monetization, and where cash flows come from

Oramed Pharmaceuticals develops orally ingestible polypeptide drugs—most prominently ORMD‑0801 oral insulin—and monetizes through a mix of licensing deals, transfer‑price product sales, milestone and royalty receipts, and strategic asset transactions. Investors should value the company as a thin but high‑leverage commercial engine: product economics are driven less by volume today and more by license terms, milestone payments and occasional one‑time strategic receipts from counterparties such as Scilex and Lifeward. For a pragmatic view into counterparty risk and revenue durability, review the relationship roll‑call below and how each agreement drives cash or clinical execution. For more relationship intelligence on life‑science counterparties visit https://nullexposure.com/.

The customer roll‑call investors need to know

Below are every counterparty referenced in Oramed’s customer‑scope results, distilled for investors with direct source notes.

Medicox (메디콕스) — exclusive Korea license for ORMD‑0801

Oramed identified Medicox as a customer under the Medicox License Agreement, which grants Medicox an exclusive 10‑year license to seek regulatory approval and distribute ORMD‑0801 in the Republic of Korea, with purchases at an agreed transfer price, up to $15k in developmental milestones, and up to 15% royalties on gross sales (Oramed 2024 Form 10‑K). A South Korean press item and industry coverage report the November 13, 2022 distribution license and the domestic exclusivity arrangement (Kormedi, March 2026; DrugDeliveryBusiness, March 2026).

Oratech Pharma — clinical trial management engagement

Oramed signed a Clinical Trial Management Agreement with Oratech Pharma effective Jan 12, 2026 to advance Oratech’s oral insulin program, with Oramed contracted to manage the trial through completion (TradingView summary, Jan 2026).

Scilex Holdings / Scilex Holding Company / Scilex — option payments, loan repurchase and warrant repurchase

Oramed received an $18 million payment from Scilex representing full satisfaction under an Option Agreement (PR Newswire / Morningstar, Jan 2026). Separately, Scilex/Scilex Holding Company figures in financing and balance‑sheet flows: Oramed’s prior senior secured loan exposure to Scilex (approx. $85 million outstanding) is referenced in a 2024 financing disclosure for Scilex, and Oramed finalized a $28.5 million warrant repurchase with Scilex on Dec 30, 2025, reflecting active settlement of prior financial arrangements (GlobeNewswire 2024; TradingView Dec 2025).

Lifeward Ltd. / Lifeward — sale of POD™ tech and equity interest

Oramed agreed to transfer its Protein Oral Drug (POD™) delivery technology to Lifeward, receiving in return up to a 49.9% beneficial ownership stake contingent on conditions plus equity, convertible notes and milestone/warrant economics; the structure includes a 4% revenue share on specified assets and up to approximately $47 million of committed capital support for Lifeward (Finviz, SahmCapital, Intellectia.ai, Jan 2026). Oramed will retain clinical management responsibility for the anticipated POD clinical program under the transaction terms (Intellectia.ai, Jan 2026).

Oravax Medical Inc — licensed IP for oral vaccine development

Oramed is a shareholder in Oravax Medical Inc and has granted exclusive licenses to Oravax (along with Premas) to develop oral COVID‑19 vaccine candidates, giving Oravax rights to Oramed’s relevant IP for that program (The Nation Thailand, FY2021).

What the relationship map implies about Oramed’s operating model

Oramed’s commercial posture is license‑centric and partnership‑driven rather than wholesale manufacturing and retail distribution. Key operating signals:

  • Contracting posture: Oramed acts primarily as a licensor and clinical program manager; contracts include long‑dated exclusive licenses (Medicox, 10 years) and option/strategic sale agreements (Lifeward, Scilex). The 10‑K explicitly identifies Medicox as a customer under ASC 606.
  • Revenue composition: Near‑term cash flows are concentrated in upfront/one‑time receipts and milestone payments (Scilex $18M, warrant/loan settlements, Lifeward structured funding) plus transfer‑price product sales to licensees where applicable (Medicox purchases ORMD‑0801 at transfer price).
  • Geographic reach and segmentation: Oramed commercial reach expands through APAC partners—Medicox carries exclusive Korean rights and regulatory obligations—illustrating a go‑to‑market strategy that outsources local commercial risk (Medicox License Agreement, 2022).
  • Criticality and concentration: The business model ties revenue criticality to a small number of strategic counterparties; license performance and milestone triggers are material to cash flow, making counterparty credit and execution risk a primary investor focus.
  • Maturity: Agreements range from early‑stage clinical management contracts (Oratech) to established license markets (Medicox) and strategic monetizations (Lifeward sale), reflecting a hybrid lifecycle in which R&D assets are progressed internally and monetized externally when appropriate.

Financial and risk implications for investors

Oramed’s public financials show limited product revenue today (Revenue TTM ~$2.0M, gross profit small) but substantive leverage from strategic receipts (reported $18M payment from Scilex and warrant/loan settlements). That creates three investor priorities:

  • Counterparty execution risk: With material payments tied to a handful of partners, monitoring counterparties’ financial health and regulatory progress is essential; the Medicox license shifts regulatory responsibility to the partner in Korea but ties royalties and purchase obligations back to Oramed (2024 10‑K).
  • Revenue durability: A portion of cash is non‑recurring (warrant repurchases, option consideration). Investors should separate recurring royalty/transfer‑price economics from one‑time strategic receipts when modeling forward revenue.
  • Strategic optionality: The Lifeward transaction converts IP into an equity and funding package that reduces near‑term capex and concentrates clinical execution while giving Oramed upside via equity and revenue share—a deliberate de‑risking of commercialization cost with retained upside (Finviz, Jan 2026).

If you want a concise counterparty exposure summary for due diligence or portfolio stress testing, see methodology and examples at https://nullexposure.com/.

Quick read: implications by counterparty (one line each)

  • Medicox — Exclusive 10‑year Korea license for ORMD‑0801 with transfer‑price purchases, milestones and up to 15% royalties (Oramed 2024 10‑K; Kormedi/DrugDeliveryBusiness, 2026).
  • Oratech Pharma — Oramed contracted to manage Oratech’s oral insulin clinical program under a Clinical Trial Management Agreement signed Jan 12, 2026 (TradingView, Jan 2026).
  • Scilex (Holdings) — $18M payment to Oramed satisfied an option agreement; prior relationships include loans and a $28.5M warrant repurchase, reflecting active settlement of financial obligations (PR Newswire / Morningstar Jan 2026; TradingView Dec 2025; GlobeNewswire 2024).
  • Lifeward Ltd. — Transfer of POD™ tech to Lifeward for equity, warrants, milestone economics and up to $47M of committed capital; Oramed to retain clinical management duties and a near‑50% potential stake (Finviz, SahmCapital, Intellectia.ai, Jan 2026).
  • Oravax Medical Inc — Oramed and partners granted Oravax exclusive licenses to develop oral COVID‑19 vaccines, reflecting prior IP licensing strategy (The Nation Thailand, FY2021).

What investors should do next

  • Track milestone and royalty receipts separately from one‑time strategic payments when modeling revenues.
  • Monitor partner credit (Scilex) and regulatory progress in Korea (Medicox) as primary execution risks.
  • Review the Lifeward equity and funding timetable for dilution or de‑risking effects on Oramed’s balance sheet.

For an investor‑grade, counterparty‑focused briefing and downloadable relationship map, visit https://nullexposure.com/. For portfolio teams needing custom exposure reports, get in touch through https://nullexposure.com/ and request an Oramed counterparty deep dive.

Bold takeaway: Oramed monetizes intellectual property through selective licensing and strategic transactions, producing episodic but material cash inflows while concentrating long‑term upside in royalties and retained equity stakes—investors must therefore underwrite counterparty execution and the split between recurring and non‑recurring cash.